Metraipolis › archive › dc_4fcbe0fec1ed

Switching from Intravenous to Subcutaneous Infliximab in Psoriasis: A Case Series on Efficacy and Treatment Satisfaction — Europe PMC PMID:41464777

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41464777
DOI
10.3390/jcm14248875
License (as archived)
solo-consultazione
Archived
2026-11-07T15:33:26.756Z
SHA-256 of the archived text
f4fc339b227250af94e2f7f2bcac3136e3ddcc0ac54de61e0b9c53c13f859b17
Stable URL of this page
https://metraipolis.com/documento/dc_4fcbe0fec1ed

How to cite

Switching from Intravenous to Subcutaneous Infliximab in Psoriasis: A Case Series on Efficacy and Treatment Satisfaction — Europe PMC PMID:41464777 — Europe PMC (en), https://europepmc.org/article/MED/41464777 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4fcbe0fec1ed (Metraipolis archive dc_4fcbe0fec1ed, sha256 f4fc339b227250af94e2f7f2bcac3136e3ddcc0ac54de61e0b9c53c13f859b17)
BibTeX
@misc{dc4fcbe0fec1ed,
  title = {Switching from Intravenous to Subcutaneous Infliximab in Psoriasis: A Case Series on Efficacy and Treatment Satisfaction — Europe PMC PMID:41464777},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41464777},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4fcbe0fec1ed; sha256 f4fc339b227250af94e2f7f2bcac3136e3ddcc0ac54de61e0b9c53c13f859b17},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41464777. Agents can read the archived copy with the MCP tool read_document.